rosiglitazone has been researched along with Hypertension in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 48 (67.61) | 29.6817 |
| 2010's | 22 (30.99) | 24.3611 |
| 2020's | 1 (1.41) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Angioni, C; Blöcher, R; Boß, M; Brüggerhoff, A; Brüne, B; Diehl, O; Geisslinger, G; Göbel, T; Grundmann, M; Hartmann, M; Heering, J; Kahnt, AS; Kaiser, A; Kostenis, E; Lamers, C; Merk, D; Proschak, E; Schader, T; Schubert-Zsilavecz, M; Steinhilber, D; Weizel, L; Wittmann, SK; Wurglics, M | 1 |
| Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM | 1 |
| Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
| Baker, HE; Breyer, MD; Cramer, MS; Harlan, SM; Heinz-Taheny, KM; Heuer, JG; Jaqua, DL; Qi, Z; Shiyanova, TL; Sullivan, JM; Wei, T | 1 |
| Arsenault, BJ; Bertrand, OF; Brassard, P; Costerousse, O; Després, JP; Laberge, AS; Piché, ME; Poirier, P | 1 |
| Li, Y; Liu, L; Liu, W; Long, J; Niu, X; Shen, S; Su, S; Yu, G; Zhao, T | 1 |
| Aslanidis, C; Buechler, C; Eisinger, K; Haberl, EM; Krautbauer, S; Neumann, M; Pohl, R; Rein-Fischboeck, L; Schacherer, D; Weiss, TS; Zimny, S | 1 |
| Aguila, MB; D'Oliveira Silva, G; de Carvalho, JJ; Mandarim-De-Lacerda, CA; Torres, TS | 1 |
| Chen, HS; Juan, CC; Lin, HD; Wu, TE | 1 |
| Gonzalez, FJ; Jia, Z; Symons, JD; Wang, N; Yang, T; Zhang, H | 1 |
| Ecelbarger, CM; Hu, J; Hu, X; Riazi, S; Tiwari, S; Wang, X | 1 |
| Glover, PH; Jones, AV; Maric, C; McLemore, GR; Racusen, LC; Reckelhoff, JF; Ryan, MJ; Sartori-Valinotti, JC; Venegas-Pont, M | 1 |
| Benagiano, V; Colantuono, G; De Benedictis, L; Federici, A; Gagliardi, S; Lorusso, L; Montagnani, M; Potenza, MA; Quon, MJ; Tiravanti, E; Zigrino, A | 1 |
| Chan, CF; Crowe, LA; Johnston, DG; Keenan, NG; Pennell, DJ; Varghese, A; Yee, MS | 1 |
| Chapman, AC; Cipolla, MJ; Roberts, TJ | 1 |
| Chan, JY; Chan, SH; Chang, AY; Ho, YH; Wu, CA; Wu, KL | 1 |
| Gao, F; Huang, C; Huang, Y; Li, R; Wang, W; Wang, X; Zhang, H | 1 |
| Bae, EH; Kim, IJ; Kim, SW; Lee, JU; Ma, SK; Park, JW | 1 |
| Sigmund, CD | 1 |
| Bae, EH; Kim, IJ; Kim, SW; Ma, SK | 1 |
| Limor, R; Oron, Y; Rosenthal, T; Stern, N; Younis, F; Zangen, S | 1 |
| Bishop, N; Cipolla, MJ; Godfrey, JA; Vinke, RS | 1 |
| Chan, JY; Chan, SH; Kung, PS; Wu, KL | 1 |
| Bu, PL; Hao, MX; Hou, XY; Li, CB; Liu, JN; Ti, Y; Wang, ZH; Zhang, W; Zhang, Y; Zhao, XQ | 1 |
| Llorens, S; Mendizábal, Y; Nava, E | 2 |
| Chen, YC; Chen, YJ; Hsiao, FC; Kao, YH; Lee, TI; Lin, YK | 1 |
| Aubert, JP; Bouée, S; Detournay, B; Fontbonne, A; Guillausseau, PJ; Halimi, S; Nachit, F | 1 |
| Abo-Warda, SM; El-Bassossy, HM; Fahmy, A | 1 |
| Leung, SW; Man, RY; Qu, C; Vanhoutte, PM | 1 |
| Brookes, ZL; Huang, L; Nauli, SM; Ong, AC; Prasad, S; Ruff, L; Solanky, T; Upadhyay, VS | 1 |
| Cherian-Shaw, M; Hammock, BD; Hye Khan, MA; Imig, JD; Nagasawa, T; Shaw, SM; Walsh, KA | 1 |
| Auclair, M; Boccara, F; Capeau, J; Capel, E; Caron-Debarle, M; Guerci, B; Lascols, O; Vigeral, C; Vigouroux, C | 1 |
| Bekins, SA; Raji, A; Seely, EW; Simonson, DC; Williams, GH | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Lavoie, MF; Schiffrin, EL; Touyz, RM | 1 |
| Grossman, E | 1 |
| Viberti, GC | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC | 1 |
| Didion, SP; Faraci, FM; Mathur, S; Ryan, MJ; Sigmund, CD | 1 |
| Beyer, A; Casavant, TL; Faraci, FM; Gackle, BD; Keen, HL; Mathur, S; Ryan, MJ; Scheetz, TE; Sigmund, CD | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
| Hitoglou-Makedou, AD; Kazakos, KA; Lasaridis, AN; Nilsson, PM; Pagkalos, EM; Pliakos, CI; Sarafidis, PA; Tourkantonis, AN; Tziolas, IM; Yovos, JG; Zebekakis, PE | 1 |
| Atkins, KB; Brosius, FC; Northcott, CA; Watts, SW | 1 |
| De Champlain, J; Wang, R; Wilson, TW; Wu, L | 1 |
| Füchtenbusch, M; Löbner, K | 1 |
| Chen, YY; Li, CM; Li, GW; Li, H; Liu, KL; Tang, YL; Wang, JP; Xing, XY; Yang, WY | 1 |
| Hitoglou-Makedou, AD; Lasaridis, AN; Nilsson, PM; Pagkalos, EM; Pliakos, CI; Sarafidis, PA; Tourkantonis, AA; Yovos, JG | 1 |
| Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Feng, SD; Hu, B; Ling, HY; Liu, XQ; Wang, BX; Zhou, SH | 1 |
| Adachi, M; Akiyama, TE; Gonzalez, FJ; Nicol, CJ | 1 |
| Abchee, AB; Alam, S; Ayach, K; Dakik, HA; Mehio-Sibai, A; Nasrallah, A; Sawaya, J; Sibai, T; Skouri, HN; Wehbeh, C | 1 |
| Hitoglou-Makedou, AD; Kazakos, KA; Lasaridis, AN; Mouslech, TF; Nilsson, PM; Sarafidis, PA; Stafylas, PC; Tourkantonis, AA; Yovos, JG | 1 |
| Laverty, R; Ledingham, JM | 1 |
| Adomaityte, J; Qayyum, R | 1 |
| Nilsson, PM; Sarafidis, PA | 1 |
| Aguiar, LG; Bahia, L; Bottino, D; Bouskela, E; Geloneze, B; Godoy-Matos, AF; Tambascia, M; Villela, N | 1 |
| Marasciulo, FL; Montagnani, M; Potenza, MA; Quon, MJ; Tarquinio, M | 1 |
| Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R | 1 |
| Beaser, RS; Levy, P | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Piccinni, MN; Pricolo, F; Salvadeo, SA | 1 |
| Ahn, KO; Bang, BK; Choi, BS; Kim, J; Kim, JY; Kim, SH; Kim, YS; Li, C; Lim, SW; Yang, CW; Yang, HJ | 1 |
| Averbukh, Z; Berman, S; Efrati, S; Ilgiyeav, E; Weissgarten, J | 1 |
| Arhancet, GB; Blanner, PM; Bolten, CW; Chott, RC; Colca, JR; Ghosh, S; Gulve, EA; Hromockyj, AE; McDonald, WG; Payne, MA; Staten, NR; Sullivan, PM | 1 |
| Hanefeld, M | 1 |
| Demidova, TIu; Erokhina, EN | 1 |
| Christopher, TA; Gao, F; Guo, W; Ji, Q; Li, J; Li, R; Lopez, BL; Ma, H; Ma, X; Wang, H; Zhang, H; Zhang, Q | 1 |
| Beck-Nielsen, H; Curtis, P; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; Pocock, SJ; Zambanini, A | 1 |
| Daubresse, JC | 1 |
| Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS | 1 |
9 review(s) available for rosiglitazone and Hypertension
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.
Topics: Animals; Blood Pressure; Disease Models, Animal; Gene Expression Regulation; Hypertension; Mice; Muscle, Smooth, Vascular; PPAR gamma; Rats; Rats, Zucker; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Topics: Albuminuria; Blood Pressure Determination; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Prognosis; Risk Assessment; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Glucose; Body Weight; C-Reactive Protein; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Research; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
A meta-analysis of the effect of thiazolidinediones on blood pressure.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2006 |
The effects of thiazolidinediones on blood pressure levels - a systematic review.
Topics: Blood Pressure; Chromans; Humans; Hypertension; MEDLINE; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2006 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Hypoglycemic Agents; Metformin; Prediabetic State; Rosiglitazone; Safety; Thiazolidinediones | 2007 |
[The importance of syndrome X in daily practice].
Topics: Anthropometry; Cardiovascular Diseases; Diet, Reducing; Exercise; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
12 trial(s) available for rosiglitazone and Hypertension
| Article | Year |
|---|---|
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.
Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Male; Metformin; Risk Reduction Behavior; Rosiglitazone | 2020 |
Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study.
Topics: Aged; Blood Glucose; Blood Pressure; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Exercise Test; Exercise Tolerance; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; PPAR gamma; Rest; Rosiglitazone | 2018 |
Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Imaging, Three-Dimensional; Magnetic Resonance Angiography; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2009 |
Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.
Topics: Aged; Blood Glucose; Blood Pressure; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2004 |
[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2004 |
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.
Topics: Aged; Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Electrolytes; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Kidney; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2005 |
The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Topics: Aged; Arteriosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fibrinogen; Homocysteine; Humans; Hypertension; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones | 2005 |
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
[Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].
Topics: Adipose Tissue; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2008 |
50 other study(ies) available for rosiglitazone and Hypertension
| Article | Year |
|---|---|
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.
Topics: 3T3 Cells; Administration, Oral; Animals; Benzamides; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Hypertension; In Vitro Techniques; Metabolic Syndrome; Mice; Microsomes, Liver; PPAR gamma; Rats; Structure-Activity Relationship | 2016 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.
Topics: Animals; Antihypertensive Agents; Creatinine; Dependovirus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Female; Genetic Vectors; Hypertension; Hypoglycemic Agents; Janus Kinases; Lac Operon; Lisinopril; Male; Mice; Nephrectomy; Nitric Oxide Synthase Type III; Renin; Rosiglitazone; Serum Albumin; Severity of Illness Index; Signal Transduction; STAT Transcription Factors | 2018 |
Rosiglitazone attenuates cell apoptosis through antioxidative and anti-apoptotic pathways in the hippocampi of spontaneously hypertensive rats.
Topics: Animals; Apoptosis; Astrocytes; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blood Pressure; Caspase 3; Hippocampus; Hypertension; Hypoglycemic Agents; Male; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Rosiglitazone | 2019 |
Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Cell Line; Cells, Cultured; Chemokines; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factors; Hep G2 Cells; Hepatic Stellate Cells; Hepatocytes; Hepcidins; Humans; Hydrocarbons, Fluorinated; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Leptin; Lipocalin-2; Liver; Liver X Receptors; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Severity of Illness Index; Sulfonamides; Thiazolidinediones; Waist-Hip Ratio; Young Adult | 2017 |
Effects of rosiglitazone (a peroxysome proliferator-activated receptor gamma agonist) on the blood pressure and aortic structure in metabolically programmed (perinatal low protein) rats.
Topics: Animals; Aorta; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Diet, Protein-Restricted; Disease Models, Animal; Elasticity; Female; Hypertension; Hypertrophy; Insulin; Leptin; Male; Nitric Oxide Synthase Type III; PPAR gamma; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Rosiglitazone; Thiazolidinediones; Tunica Media | 2008 |
Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Chaperonin 60; Diabetes Mellitus, Experimental; Disease Models, Animal; Fructose; Gene Expression; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Myocardium; Rats; Rats, Sprague-Dawley; Rosiglitazone; Streptozocin; Thiazolidinediones | 2009 |
Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.
Topics: Animals; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Femoral Artery; Hypertension; Male; Mice; Mice, Knockout; Muscle, Smooth, Vascular; PPAR gamma; Rosiglitazone; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents | 2009 |
Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Humans; Hypertension; Hypoglycemic Agents; Kidney; Metabolic Syndrome; Obesity; PPAR gamma; Rats; Rats, Zucker; Receptor, Angiotensin, Type 1; Rosiglitazone; Sodium Chloride, Dietary; Tetrazoles; Thiazolidinediones; Thinness | 2009 |
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Pressure; Chemokine CCL2; Disease Models, Animal; Endothelin-1; Female; Hypertension; Kidney; Kidney Diseases; Lupus Erythematosus, Systemic; Macrophages; Mice; Monocytes; Osteopontin; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature.
Topics: Animals; Antioxidants; Blood Vessels; Cardiovascular System; Cattle; Cells, Cultured; Drug Evaluation, Preclinical; Hypertension; Male; NADPH Oxidases; Oxidative Stress; Phenotype; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones | 2009 |
PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Brain Edema; Capillary Permeability; Cerebral Veins; Cerebrovascular Circulation; Chronic Disease; Cyclic N-Oxides; Disease Models, Animal; Female; Hydrostatic Pressure; Hypertension; NG-Nitroarginine Methyl Ester; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Spin Labels; Thiazolidinediones; Time Factors | 2009 |
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension.
Topics: Adenosine Triphosphate; Angiotensin II; Animals; Antioxidants; Blood Pressure; Blood Vessels; Catalase; Cell Respiration; Cyclic N-Oxides; Disease Models, Animal; Enzyme Inhibitors; Homeostasis; Humans; Hydrogen Peroxide; Hypertension; Imidazoles; Ion Channels; Male; Medulla Oblongata; Microinjections; Mitochondria; Mitochondrial Proteins; NADPH Oxidases; Onium Compounds; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphorylation; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Rosiglitazone; Spin Labels; Superoxide Dismutase; Superoxide Dismutase-1; Superoxides; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Transcription Factors; Transcriptional Activation; Transduction, Genetic; Uncoupling Protein 2; Up-Regulation | 2009 |
Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling.
Topics: Animals; Aorta; Arteries; Disease Susceptibility; Endothelium, Vascular; Gene Expression Regulation; Hypertension; Insulin; Insulin Resistance; Male; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; Vasodilation | 2010 |
Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats.
Topics: Animals; Biomarkers; Blood Pressure; Blotting, Western; Desoxycorticosterone; Glomerulonephritis; Hypertension; Hypoglycemic Agents; Immunoenzyme Techniques; Inflammation; Male; Mineralocorticoids; Nephritis, Interstitial; PPAR gamma; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Sodium Chloride, Dietary; Thiazolidinediones | 2010 |
Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.
Topics: Animals; Cyclooxygenase 2; Desoxycorticosterone; Disease Models, Animal; Endothelin-1; Glomerulonephritis; HSP27 Heat-Shock Proteins; Hypertension; Kidney; Male; Nephritis, Interstitial; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1 | 2010 |
Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hyperglycemia; Hypertension; Insulin; Insulin Resistance; Leptin; PPAR gamma; Rats; Rats, Inbred SHR; Rosiglitazone; Telmisartan; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Gain | 2010 |
PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats.
Topics: Animals; Blood Pressure; Brain; Capillaries; Cerebral Arteries; Enzyme Inhibitors; Female; Hypertension; Hypoglycemic Agents; NG-Nitroarginine Methyl Ester; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats.
Topics: Administration, Oral; Amlodipine; Analysis of Variance; Animals; Blood Pressure; Disease Models, Animal; Heart Rate; Hypertension; Kidney Medulla; Male; Oxidative Stress; PPAR gamma; Probability; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Up-Regulation; Vasodilator Agents | 2010 |
Rosiglitazone attenuates myocardial remodeling in spontaneously hypertensive rats.
Topics: Animals; Collagen Type I; Collagen Type III; Hypertension; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; NF-kappa B; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factor AP-1; Treatment Outcome; Ultrasonography; Up-Regulation; Ventricular Remodeling | 2011 |
Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelium, Vascular; Epinephrine; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Hypoglycemic Agents; Indomethacin; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitroprusside; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones; Thromboxane A2; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents | 2011 |
Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration.
Topics: Animals; Arrhythmias, Cardiac; Calcium Signaling; Diabetes Mellitus; Hypertension; Male; Myocytes, Cardiac; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones | 2013 |
A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.
Topics: Adult; Aged; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; France; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Rosiglitazone; Smoking; Surveys and Questionnaires; Thiazolidinediones; Time Factors; Treatment Outcome | 2012 |
Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
Topics: Animals; Blood Glucose; Blood Pressure; Blood Vessels; Calcium; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Male; Nitric Oxide; Potassium Chloride; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides | 2012 |
Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha.
Topics: Animals; Aorta, Thoracic; Fenofibrate; Hypertension; In Vitro Techniques; Male; Peroxisome Proliferators; PPAR alpha; PPAR gamma; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones; Vasoconstriction | 2012 |
Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.
Topics: Animals; Antioxidants; Arterioles; Calcium; Capillary Permeability; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Genotype; Heterozygote; Hypertension; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myography; Nitric Oxide; Oxidative Stress; Peroxynitrous Acid; Phenotype; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Renal Insufficiency; Reperfusion Injury; Rosiglitazone; Superoxides; Thiazolidinediones; Time Factors; TRPP Cation Channels; Vasodilation; Vasodilator Agents; Venules | 2013 |
Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.
Topics: Albuminuria; Animals; Blood Pressure; Cardiomegaly; Epoxide Hydrolases; Hypertension; Hypoglycemic Agents; Kidney Glomerulus; Macrophages; Male; Obesity; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Species Specificity; Syndrome; Thiazolidinediones | 2012 |
Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Topics: Adult; Aged; Amino Acid Sequence; Angiotensin II; Anilides; Animals; Case-Control Studies; Enzyme Activation; Female; Fibroblasts; Genetic Predisposition to Disease; HEK293 Cells; Humans; Hypertension; Inflammation Mediators; Leukocytes, Mononuclear; Lipodystrophy, Familial Partial; Male; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Muscle, Smooth, Vascular; Mutation; Myocytes, Smooth Muscle; Oxidative Stress; Phenotype; PPAR gamma; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA Interference; Rosiglitazone; Severity of Illness Index; Skin; Thiazolidinediones; Transfection; Young Adult | 2013 |
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Oxygen; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tunica Media; Vascular Resistance; Vasodilator Agents | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; Endothelins; Fenofibrate; Fibrosis; Heart; Heart Ventricles; Hypertension; Myocardium; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Remodeling | 2003 |
PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.
Topics: Angiotensinogen; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Endothelium, Vascular; Humans; Hypertension; Mice; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Renin; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vasodilation | 2004 |
Gene expression profiling of potential PPARgamma target genes in mouse aorta.
Topics: Animals; Aorta; Gene Expression Profiling; Gene Expression Regulation; Hypertension; Inflammation; Male; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
Effects of PPAR-gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries.
Topics: Animals; Aorta; Arteries; Biomarkers; Blood Pressure; Carotid Arteries; Chromans; Deoxyglucose; Desoxycorticosterone; Glucose Transporter Type 4; Hypertension; Ligands; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Smooth, Vascular; PPAR gamma; Prostaglandin D2; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sodium Chloride; Thiazolidinediones; Troglitazone | 2005 |
Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Hypertension; Hypertrophy, Left Ventricular; Kidney; Male; Myocardium; Organ Size; Peroxisome Proliferators; PPAR alpha; PPAR gamma; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Tachycardia; Thiazolidinediones; Weight Gain | 2004 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; Fructose; Hydrolases; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
[Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension].
Topics: Animals; Aorta; Hypertension; Insulin Resistance; Male; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vasodilation; Vasodilator Agents | 2005 |
PPARgamma in endothelial cells influences high fat diet-induced hypertension.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dietary Fats; Dose-Response Relationship, Drug; Endothelial Cells; Female; Heart Rate; Hypertension; Ligands; Male; Mice; Mice, Knockout; PPAR gamma; Rosiglitazone; Sodium Chloride; Thiazolidinediones | 2005 |
Prevalence of coronary artery calcium among asymptomatic men and women in a developing country: comparison with the USA data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Calcinosis; Calcium; Comorbidity; Coronary Artery Disease; Coronary Vessels; Developing Countries; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; Lebanon; Male; Middle Aged; Prevalence; Risk Factors; Rosiglitazone; Smoking; Thiazolidinediones; Tomography, X-Ray Computed; United States | 2005 |
Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Basilar Artery; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Mesenteric Arteries; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Wistar; Rosiglitazone; Simvastatin; Tetrazoles; Thiazolidinediones; Tunica Media; Valine; Valsartan | 2005 |
Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome.
Topics: Acetylcholine; Adiponectin; Adult; C-Reactive Protein; Endothelium, Vascular; Female; Glucose Tolerance Test; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones | 2007 |
Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Enalapril; Hypertension; Insulin; Insulin Resistance; Rats; Rats, Inbred SHR; Reference Values; Rosiglitazone; Thiazolidinediones; Vasoconstriction; Vasodilation | 2006 |
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; Disease Models, Animal; Encephalitis; Hypertension; Intercellular Adhesion Molecule-1; Ischemic Attack, Transient; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Neuroprotective Agents; Pioglitazone; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Superoxide Dismutase-1; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones | 2007 |
Metabolic syndrome: a work in progress, but a useful construct.
Topics: Abdominal Fat; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Models, Biological; Obesity; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Renoprotective effects of rosiglitazone in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Stroke; Thiazolidinediones | 2007 |
PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Hypertension; Mesangial Cells; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat.
Topics: Adiponectin; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Disease Models, Animal; Disease Progression; Heart Rate; Hypertension; Insulin; Lipids; Male; PPAR gamma; Pyridines; Rats; Rats, Inbred Dahl; Rosiglitazone; Sodium Chloride, Dietary; Thiazolidinediones | 2007 |
Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension.
Topics: Acetylcholine; Animals; Aorta; Dose-Response Relationship, Drug; Endothelium, Vascular; Hypertension; Indomethacin; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phenylephrine; Pioglitazone; Prostaglandins; Rats; Rats, Inbred SHR; Rosiglitazone; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents | 2007 |
Reduced cardiotropic response to insulin in spontaneously hypertensive rats: role of peroxisome proliferator-activated receptor-gamma-initiated signaling.
Topics: Animals; Disease Models, Animal; Gene Expression; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Myocardial Contraction; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; PPAR gamma; Rats; Rats, Inbred WKY; Rosiglitazone; Signal Transduction; Thiazolidinediones; Vasodilator Agents | 2008 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2002 |